Osteologix's NB S101 meets osteoporosis endpoint

OLGX said NB S101 (formerly NBS-101) met the primary endpoint of a significant reduction in serum CTX-1 levels vs. placebo in the Phase II STRONG trial to treat osteoporosis in 289 postmenopausal wome...